SMS Pharma reports 60% yoy decline in PAT for Q4FY22; logs revenue of Rs60.90 crore

2 Jun 2022 , 04:06 PM

SMS Pharmaceuticals Limited, a Hyderabad-based diversified and fully integrated pharmaceutical company, with interests in Active Pharmaceutical Ingredients (API) and Intermediates announced its financial results for the quarter and financial year ended March 31, 2022.

The company has reported revenue of Rs519.90 crore in FY22 as compared to Rs563.20 crore in the previous financial year, down by 8% yoy. The company has witnessed a sharp decline of 64% yoy at Rs60.90 crore in Q4FY22 as compared to Rs171.30 crore in the same quarter previous year.

Company reported an EBITDA of Rs119.50 crore in FY22 as against Rs124.60 crore in FY21, down by 4% yoy. The company has posted a negative EBITDA of Rs4 crore in Q4FY22 as compared to positive Rs42.40 crore in Q4FY21.

PAT for the financial year ended March 31, 2022, was reported at Rs67.90 crore as compared to Rs61 crore in the previous financial year, up by 11% yoy. However, PAT for the quarter under review declined 60% yoy at Rs8.90 crore as compared to Rs22.20 crore in Q4FY21.

EBITDA Margin stood at 23% in FY22, and 14.60% in Q4FY22. PAT margin for FY22 was reported at 13.10%, and 14.60% for Q4FY22.

SMS Pharma ended at Rs81.50 up by Rs0.25 or 0.31% from its previous closing of Rs81.25 on the BSE.